Kornimate/medical-research-clean huggingface dataset:
tobacco assessment and intervention with low-income persons living with hiv-aids (plwha) in community-based aids service organizations

Conditions: Tobacco Cessation; HIV; AIDS

Summary: "a treatment session especially for plwha to help them discuss and take action about their smoking may be useful."


Eligibility criteria:
inclusion criteria: * age 18 years or older as per self-report; * english speaking; * new york or new jersey state resident; * hiv-positive serostatus direct referral from a cab agency staff member, which verifies that the person is an hiv+ client, or by as verified by presentation of medical evidence (i.e.,confirmatory test result, arv prescription, m11q form, or lab results); * self-report of smoking \> or = to 20 cigarettes (\> or = to one pack) within the prior 7 days; * to confirm smoking status, the carbon monoxide alveolar breath test must be \> or = to 10 ppm; * to confirm cognitive functioning, score on the in-person blessed exam must be \< or = to 10; * low income, defined by either: 1) proof of medicaid insurance, or 2) self-report of income at 50% or below median income for new york state for new york state residents, or if a new jersey resident, at or below 50% median income for new jersey exclusion criteria: * presence of current severe psychopathology that would limit study participation (e.g., unstable schizophrenia, bipolar disorder recent changes to medication noncompliance); * currently receiving smoking cessation treatment elsewhere.

Keywords: tobacco use assessment smoke tobacco quit smoking tobacco cessation hiv/aids community-based service organizations 11-173 low-income persons living with hiv/aids
endotracheal intubation with sevoflurane in surgical pediatric patients

Conditions: Anesthesia; Reaction

Summary: aim of the study is to compare the optimal time needed for successful tracheal intubation with immediate 8% sevoflurane and incremental sevoflurane induction in surgical pediatric patients undergoing adenotonsillectomy without using muscle relaxants or opioids

investigators studied 100 pediatric surgical patients admitted to sulaimani teaching hospital in the otorhinolaryngology, head and neck surgical department, from the first of june 2011 to the first of september 2011, children aged 2-7 years,both genders, asa physical statuses і and ii (asa i: a healthy normal patient, while asa ii: a patient with mild systemic disease with no functional limitations) were scheduled for elective adenotonsillectomy operations. they were randomly divided into two equal groups according to the induction method. group 1 (g1) using incremental induction with sevoflurane (1-8 %) in 100% o2, the vapor concentration is increased by 1% every few breaths. group 2 (g2) high concentration of sevoflurane (8%) in 100% o2 from the beginning of induction. none of them is given premedication or any other adjunct drugs until successful intubation is done; ventilation was assisted and then controlled when possible. if upper airway obstruction occurred, an oropharyngeal airway was immediately inserted. attempts were made to obtain venous access before laryngoscopy. all patients monitored with electrocardiography (ecg), noninvasive blood pressure monitoring (nibp), pulse oximetry, and temperature measurements. children with extreme weight, suspicion of difficult airway, moved during laryngoscopy, or more than one trial of laryngoscopy needed were excluded from this study. the endotracheal tube (ett) size was selected by using the formula (age/4) + 4.5. only a single laryngoscopy attempt was allowed. small, brief movements of extremities occurring after (ett) placement did not considered as exclusion criteria. anesthesia was delivered by anesthetic machine (datex ohmeda), using an ayer's t-piece with jackson ree's modification system, with a fresh gas flow of 6 l/min through a sevoflurane vaporizer. patients were observed until eyelash reflex disappears, pupils centered and constricted. jaw relaxation and movements were monitored. ventilation was controlled till the time of laryngoscopy; the vocal cords were completely visible, orotracheal intubation done with macintosh laryngoscope blade size 2 by the same anesthetist for all the patients. the time from induction until successful tracheal intubation is recorded.

Eligibility criteria:
inclusion criteria: * children 2-7 years old american society of anesthesiologists physical status class 1 and 2 scheduled for elective adenotonsillectomy operations exclusion criteria: * children with extreme weight, suspicion of difficult airway, moved during laryngoscopy, or more than one trial of laryngoscopy needed

Keywords: induction pediatrics sevoflurane intubation time
effect of preoperative curcumin in breast cancer patients

Conditions: Breast Cancer

Summary: effect of curcumin on modulation of immune and inflammatory parameters in pre-operative patients

patients diagnosed with breast cancer will be supplemented with either curcumin or placebo for a minimum period of 2 weeks and may be extended up to 4 weeks prior to their surgery.

Eligibility criteria:
inclusion criteria: * patients with operable breast cancer * life expectancy of at least 3 months * adequate organ function * no allergy to curcumin * provides consent to participate in trial and adhere to the study protocol exclusion criteria: * receiving concomitant radiotherapy, hormonal, immune therapy or other investigational drugs * uncontrolled concurrent illness * patient of anti platelet medications * pregnant / breast feeding * patients who are unable or unwilling to take curcumin, herbal remedies, or non-prescription medications * patients with bleeding tendency, bleeding disorders and abnormal bleeding/clotting profile
immunological follow-up of patients with basedow's orbitopathy

Conditions: Graves Orbitopathy

Summary: graves' disease is characterized by the combination of anti-tsh receptor antibodies (thyroid-stimulating hormone or thyroidotropic hormone), specific to this disease, with inconsistent symptoms such as hyperthyroidism, orbitopathy, goiter, or myxedema dermatological involvement. the activation of tsh receptors (rtsh) by these antibodies (known as "trak") causes the secretion of thyroid hormones as well as the development of the thyroid gland, responsible for a goiter. the cellular infiltrate responsible for the goiter consists mainly of t-lymphocytes but also of activated b lymphocytes secreting trak. although graves' disease is antibody mediated, cytokine secretion by th1 therefore seems essential to pathogenesis. the treatment of orbitopathy requires primarily euthyroidism and the discontinuation of smoking. despite these measures, moderate to severe attacks may require immunomodulatory treatment to limit local inflammation. this treatment is currently based on a first-line corticosteroid treatment (per os or preferably by weekly intravenous infusions). in the context of inadequate response, the therapeutic strategy is not very well established since some immunosuppressive treatments targeting b-cells or t- cells have been studied but with little benefit. many new concepts concerning immune tolerance and autoimmunity have emerged in recent years, particularly in graves' disease, with sometimes complex cellular interactions. certain mechanisms could occur either independently or in combination: i) modulation of t cell activation, differentiation and apoptosis; ii) inhibition of bl maturation and immunoglobulin production; iii) alteration of the balance between t helper (th)-17 and t regulatory lymphocytes (treg), by promoting treg differentiation and inhibiting th17 differentiation.


Eligibility criteria:
inclusion criteria: * patients aged 18 to 80 years included * subjects with grave's disease and unsuccessful or intolerant to corticosteroid bolus therapy (eugogo protocol) * subjects with positive traks exclusion criteria: * current treatment or within 6 months before inclusion by anti-cd20 monoclonal antibodies * current treatment or in the month prior to inclusion with corticosteroids \>10 mg/day (oral or intravenous)

Keywords: graves orbitopathy trak immune monitoring
aminocamptothecin in treating patients with recurrent or refractory ovarian epithelial cancer or primary cancer of the peritoneum

Conditions: Ovarian Cancer; Primary Peritoneal Cavity Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of aminocamptothecin in treating patients with recurrent or refractory ovarian epithelial cancer or primary cancer of the peritoneum.

objectives: i. estimate the antitumor activity of aminocamptothecin colloidal dispersion in patients with platinum-resistant recurrent or refractory ovarian cancer or primary peritoneal carcinoma who have failed on higher priority treatment protocols. ii. determine the nature and degree of toxicity of aminocamptothecin colloidal dispersion in this patient population. outline: patients receive aminocamptothecin colloidal dispersion iv over 120 hours weekly for two of every three weeks. courses are repeated every 21 days in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months for 2 years, then every 6 months for 3 years. projected accrual: approximately 23-56 patients will be accrued for this study within 5-12 months.

Eligibility criteria:
disease characteristics: histologically confirmed recurrent or persistent ovarian epithelial cancer or primary peritoneal carcinoma progressive disease on platinum-based treatment alone or in combination two prior treatment regimens allowed only if other regimen was paclitaxel or recurrence within 6 months of chemotherapy measurable disease not eligible for a higher priority gog protocol patient characteristics: age: 13 and over performance status: gog 0-2 life expectancy: not specified hematopoietic: wbc at least 3,000/mm3 platelet count at least 100,000/mm3 granulocyte count at least 1,500/mm3 hepatic: bilirubin no greater than 1.5 mg/dl sgot/sgpt no greater than 2.5 times upper limit of normal (uln) alkaline phosphatase no greater than 2.5 times uln renal: creatinine no greater than 1.5 mg/dl other: no significant infection not pregnant fertile patients must use effective contraception at least 5 years since prior malignancy; no prior chemotherapy or radiotherapy for that malignancy no concurrent malignancy other than non-melanoma skin cancer prior concurrent therapy: biologic therapy: at least 4 weeks since prior biologic therapy chemotherapy: see disease characteristics at least 4 weeks since prior chemotherapy and recovered no prior treatment with aminocamptothecin endocrine therapy: at least 4 weeks since prior endocrine therapy radiotherapy: at least 4 weeks since prior radiotherapy and recovered no prior radiotherapy to site(s) of measurable disease used on this trial no prior radiotherapy to more than 25% of marrow-bearing areas surgery: at least 4 weeks since prior surgery

Keywords: recurrent ovarian epithelial cancer primary peritoneal cavity cancer
novel combined function test for patients on peritoneal dialysis

Conditions: End Stage Kidney Disease (ESRD)

Summary: peritoneal membrane function tests such as the traditional peritoneal equilibrium test (pet) aid in the assessment of various peritoneal membrane functions, and are widely used in clinical practice to guide dialysis prescription, and also to monitor the integrity of the peritoneal membrane over time. traditional tests do however have several shortcomings such as being time consuming, complex, and having a low reliability. also, present functional tests often provide limited information such as small solute transfer rates, which means that other functional changes go unnoticed. the present study investigates the reliability of a novel short (60 min) test, with the potential of replacing complex and time-consuming conventional tests. the novel test provides a comprehensive assessment on both water- and solute transfer across the peritoneal membrane, including the osmotic conductance to glucose (ocg), small solute diffusive conductance (in terms of the diffusive surface to diffusion length ratio, a0/δx), and also macromolecular transport and apparent fluid absorption. in contrast to conventional tests, multiple fill volumes may be used and results are also applicable to all glucose strengths used in conventional peritoneal dialysis.


Eligibility criteria:
inclusion criteria: * peritoneal dialysis treatment duration of at least 1 month * no recent peritonitis (a minimum of 1 month since the last peritonitis) exclusion criteria: * pregnancy * participant unable to provide informed consent * peritonitis * other acute infections

Keywords: peritoneal dialysis peritoneal equilibration test combipet
effect of botulinum toxin in neurogenic bladders in children with myelomeningocele

Conditions: Myelomeningocele; Bladder, Neurogenic

Summary: the purpose of this study is to examine how injection of botulinum toxin in the bladder affects bladder function. the trial is carried out in children born with malformation of the spinal cord and subsequent overactive bladders. the purpose of treating the bladder (with different drugs) is to prevent damage to the kidneys and renal function. the aim of this study is to compare a conventionally used drug (oxybutynin) with botulinum toxin. the hypothesis of the study is that botulinum toxin is equal to oxybutynin in the treatment of overactive bladder.

neurogenic bladder is often seen in children with myelomeningocele, tumors in the spinal canal, or a traumatized spinal cord. the majority of the patients have high pressure bladders which can lead to reflux and frequent infections in the urinary tract. although children experience insufficient bladder emptying, many of them also experience urinary incontinence and have to perform clean intermittent catheterization (cic). if no intervention is made, the children are at high risk of renal deterioration.

Eligibility criteria:
inclusion criteria: * myelomeningocele * neurogenic bladder with untreated leak point pressures \> 40 mmh2o * treated with oxybutynin or other parasympatholytics exclusion criteria: * acute urinary tract infection * compromised neuromuscular transmission

Keywords: myelomeningocele neurogenic bladder intervention botulinum a toxin oxybutynin
comparison of primary long full coverage stenting vs primary short spot stenting for long femoropopliteal artery disease.

Conditions: Claudication

Summary: hypothesis: primary long full coverage stenting is superior to primary short spot stenting in the treatment of long (≥80 mm) femoropopliteal artery lesions. study design : * prospective, randomized, multi-center study * a total of 220 subjects with symptomatic peripheral artery disease of lower limbs who meet all inclusion and exclusion criteria will be included. * patients will be randomized in a two by two factorial manner according to the strategy of stenting (long versus short stenting) and the additional use of cilostazol. each randomization of the enrolled subjects will be done 1:1. * patients will be followed clinically for 1 year after the procedure. * angiographic or ct follow-up will be performed at 1 year.


Eligibility criteria:
inclusion criteria: clinical criteria: 1. age 20 years of older 2. symptomatic peripheral artery disease: * moderate or severe claudication (rutherford category 2 or 3) * critical limb ischemia (rutherford category 4 or 5) 3. patients with signed informed consent anatomical criteria: 1. target lesion length ≥80 mm by angiographic estimation 2. stenosis of more than 50 percent or occlusion of the ipsilateral superficial femoral artery 3. at least one patent (less than 50 percent stenosed) tibioperoneal runoff vessel. exclusion criteria: clinical criteria 1. acute critical limb ischemia 2. severe critical limb ischemia (rutherford category 6) 3. major bleeding history within prior 2 months 4. known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel or contrast agents 5. age \> 85 years 6. severe hepatic dysfunction (\> 3 times normal reference values) 7. significant renal dysfunction (serum creatinine \> 2.0 mg/dl 8. significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis 9. lvef \< 40% or clinically overt congestive heart failure 10. pregnant women or women with potential childbearing 11. life expectancy \<1 year due to comorbidity angiographic criteria 1. previous bypass surgery or stenting of the superficial femoral artery 2. untreated inflow disease of the ipsilateral pelvic arteries (more than 50% stenosis or occlusion)
a european post-authorisation observational study of patients with hereditary angioedema

Conditions: Hereditary Angioedema (HAE)

Summary: this observational (non-interventional) study is being conducted to characterize the safety and use of cinryze in routine clinical practice when administered for (1) routine prevention of angioedema attacks, (2) pre-procedure prevention of angioedema attacks, and/or (3) treatment of angioedema attacks.


Eligibility criteria:
inclusion criteria all patients must: * have a diagnosis of hae and be receiving cinryze for prevention or treatment of angioedema attacks * provide written informed consent/assent in compliance with applicable country-specific and local regulations exclusion criteria all patients must not: * be receiving cinryze in an investigational study * be receiving another hae therapy as part of a clinical trial
neurophysiological mechanisms involved in knee osteoarthritis

Conditions: Knee Osteoarthritis; Chronic Pain

Summary: introduction: total knee arthroplasty (tka) is an effective intervention to relieve people with osteoarthritis (oa). nevertheless, 15 to 30% of patients continue to experience severe pain following surgery. recent data suggest that central nervous system (cns) changes may play a role in oa pain and possibly explain why some patients have poorer clinical outcomes following tka. objectives: our main objectives are to explore the relationship between oa pain and (1) the integrity of corticospinal system, (2) the efficacy of descending pain inhibition circuits. methods: fifty-two patients waiting for tka will be recruited. the integrity of the corticospinal projections will be measured using transcranial magnetic stimulation (recruitment curve of the affected quadriceps femoris muscle) and the descending pain inhibition circuits (bulbospinal projections) will be assessed by a counter-irritation paradigm (i.e., conditioned pain modulation with immersion of the arm in painfully cold water). diffuse tension imaging (dti) will also be used to quantify the strength of these corticospinal and bulbospinal projections. clinical outcomes will be evaluated before and after arthroplasty with a series of validated questionnaires such as the womac scale, the mcgill pain questionnaire and the brief pain inventory. these different neurophysiological and clinical measures will be taken before surgery, 6 months after surgery and 1 year post-surgery. anticipated results: the investigators expect a moderate association between pain and the strength of the corticospinal and bulbospinal projections. moreover, it is expected that there will be a moderate association between the strength of the corticospinal/bulbospinal projections and the clinical evolution of patients.

see outcome measures

Eligibility criteria:
inclusion criteria: * being an adults aged 50-79 years old with a diagnosis of knee oa and waiting for a primary arthroplasty * refrain from consuming cigarettes and caffeine 2 hours and 6 hours before testing, respectively * refrain from taking short-acting analgesics (e.g., acetaminophen) 6 hours before testing exclusion criteria: * having difficulty understanding french language * having a diagnosis of neurological disorder or diagnosis of chronic pain (other knee oa) * having metal implants in the skull * having pacemaker or neurostimulator * being pregnant * being epileptic

Keywords: arthritis chronic pain transcranial magnetic stimulation (tms) magnetic resonance imaging (mri) conditioned pain modulation (cpm) clinical measures knee osteoarthritis
quantitative ultrasound with liver incytes for evaluation of non-alcoholic fatty liver disease

Conditions: NAFLD; NASH - Nonalcoholic Steatohepatitis

Summary: the purpose of this study is to prospectively evaluate the utility of liver incytes in assessing nafld with or without advanced fibrosis in patients seen in liver clinics for suspected nafld diagnosis.

the proposed study will evaluate the performance characteristics of lsm as a measure of fibrosis and ace as a measure of hepatic steatosis by liver incytes in patients with different stages of nafld. in addition, the diagnostic accuracy of ace will be compared to cap and lsm as measured by liver incytes to that measured by fibroscan® using liver histology as the reference standard. the performance of these two methods will also be compared to that of non-invasive blood based markers such as apri, fib4, and nafld fibrosis score in predicting advanced fibrosis in biopsy proven nafld.

Eligibility criteria:
inclusion criteria: 1. adults aged 21 years or older 2. suspected nafld or nash with plans to undergo standard of care liver biopsy 3. history of biopsy proven nafld or nash within 6 months prior to enrollment 4. planned liver biopsy for evaluation of nafld within 6 months of enrollment 5. ability to provide informed consent exclusion criteria: 1. fasting for less than three hours prior to the scan 2. subject is a pregnant or lactating female 3. subject with current, significant alcohol consumption or history of significant alcohol consumption for a period of more than 3 consecutive months any time within 1 year prior to screening. significant alcohol consumption is defined as more than 20 gram per day in females and more than 30 grams per day in males, on average (a standard drink in the us is considered to be 14 grams of alcohol). 4. subject is unable to reliably quantify alcohol consumption based upon local study physician judgment. 5. subject uses drugs historically associated with nafld (amiodarone, methotrexate, systemic glucocorticoids, tetracyclines, tamoxifen, estrogens at doses greater than those used for hormone replacement, anabolic steroids, valproic acid, and other known hepatotoxins) for more than 2 weeks in the year prior to screening 6. subject with history of cirrhosis or clinical evidence of hepatic decompensation as defined by the presence of any of the following abnormalities at screening 1. serum albumin less than 3.5 grams/deciliter (g/dl). 2. inr greater than 1.5. 3. direct bilirubin greater than 1.3 milligrams per deciliter (mg/dl). 7. subject has a history of bleeding esophageal varices, ascites or hepatic encephalopathy 8. subject has history of other forms of chronic liver diseases such as viral hepatitis, autoimmune hepatitis, cholestatic liver disease (primary biliary cirrhosis or primary sclerosing cholangitis). 9. subject with active substance abuse 10. acute hepatitis defined as ast/alt \> 500 u/l 11. patients with a pacemaker or defibrillator 12. ascites